Developing new cancer drugs is expensive. Before a new cancer drug goes to trial it is developed for a year or two, and costs around $100 million. Also, 95% of cancer drugs fail in clinical trials meaning there are lots of misses before a hit. Berg, a biotech startup, wants to harness artificial intelligence to develop the next generation of cancer treatments. The company has created BPM 31510, the first cancer drug developed by artificial intelligence being tested in clinical studies. When cancer spreads mitochondria that usually tell damaged cells to die go crazy, and spread. BPM 31510 focuses on the mitochondria, and tries to restore a normal cell’s dying process. Though BPM 31510 is still in early trial stages, it could hint at how future drugs will be developed.
The next frontier in medicine: drugs designed by artificial intelligence
More of Today's Solutions
This radio station plays ethereal ambient music made by trees
Silent tree activity, like photosynthesis and the absorption and evaporation of water, produces a small voltage in the leaves. In a bid to encourage ...
Read MoreCanada outlines plan to ban single-use plastic
Canada has now become a world leader in environmental policy. On Monday, it laid out its final plans and regulations on how it intends ...
Read MoreArchitects embrace trees to bring nature in and redefine home design
BY THE OPTIMIST DAILY EDITORIAL TEAM Biophilic design—the practice of integrating nature into architecture—is no longer confined to houseplants and scenic views. Architects and ...
Read MoreWhy Icelanders are getting happier every year – and what we can learn from them
BY THE OPTIMIST DAILY EDITORIAL TEAM In a world where happiness in so many places is slowly declining, Iceland is going against the grain. ...
Read More
